Immunohistochemical and polymerase chain reaction (PCR) analyses of human prostate tissues suggest that SRD5A1 and SRD5A2 levels change with prostate cancer development and progression [7], [8], [9]. This evidence concerns the gene SRD5A2 and prostate carcinoma.